Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

HURA

+ Watchlist+ Portfolio

TuHURA Biosciences, Inc.

Regulated industrySells to businessesDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$1.40
52-Week Range
$0.41 – $3.43
Market Cap
$90.09M
P/E (TTM)
—
EPS (TTM)
-0.50
Dividend Yield
0.00%
Advanced Metrics
Price/Book
4.82
PEG Ratio
—
Return on Equity
-167.53%
Return on Assets
-60.45%
Gross Margin
0.00%
Operating Margin
0.00%
Profit Margin
0.00%
Current Ratio
0.47
Debt/Equity
0.52
Total Debt
$9.90M
Free Cash Flow
$-17.24M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$98.37M

Market Snapshot

About

TuHURA Biosciences, Inc. is a clinical-stage biopharmaceutical company developing therapies for patients with cancer. The company's pipeline includes multiple product candidates targeting various oncology indications, with a focus on small molecule inhibitors and novel mechanisms of action. TuHURA's lead programs include IMP-1734, an oral inhibitor being developed for solid tumors, and other candidates in preclinical and clinical development stages. The company utilizes a platform approach to drug discovery and development, focusing on precision medicine and biomarker-driven patient selection. TuHURA Biosciences was formerly known as Coronado Biosciences and rebranded to reflect its new strategic focus on oncology therapeutics. The company is headquartered in San Diego, California.